Amgen (NASDAQ:AMGN – Get Free Report) will release its earnings data before the market opens on Wednesday, October 30th. Analysts expect Amgen to post earnings of $5.13 per share for the quarter. Amgen has set its FY24 guidance at $19.10-20.10 EPS and its FY 2024 guidance at 19.100-20.100 EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter last year, the business posted $5.00 earnings per share. The business’s revenue was up 20.1% compared to the same quarter last year. On average, analysts expect Amgen to post $19 EPS for the current fiscal year and $21 EPS for the next fiscal year.
Amgen Trading Up 0.9 %
Shares of Amgen stock opened at $319.66 on Wednesday. The stock has a fifty day moving average price of $325.93 and a 200-day moving average price of $313.11. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The firm has a market cap of $171.48 billion, a PE ratio of 45.67, a P/E/G ratio of 2.86 and a beta of 0.61. Amgen has a 1 year low of $249.70 and a 1 year high of $346.85.
Amgen Dividend Announcement
Wall Street Analyst Weigh In
A number of analysts have issued reports on AMGN shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Argus boosted their price objective on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price (up previously from $375.00) on shares of Amgen in a research report on Wednesday, August 7th. Truist Financial lowered shares of Amgen from a “buy” rating to a “hold” rating and boosted their price target for the company from $320.00 to $333.00 in a research report on Monday, October 14th. Finally, Morgan Stanley reduced their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average target price of $332.55.
View Our Latest Stock Analysis on Amgen
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
- Five stocks we like better than Amgen
- Differences Between Momentum Investing and Long Term Investing
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Technology Stocks Explained: Here’s What to Know About Tech
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.